Masimo Co. (NASDAQ:MASI) COO Bilal Muhsin Sells 30,000 Shares

Masimo Co. (NASDAQ:MASI) COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Masimo Trading Up 0.7 %

MASI traded up $1.15 during midday trading on Wednesday, reaching $167.67. 943,106 shares of the company’s stock traded hands, compared to its average volume of 625,181. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The stock has a market capitalization of $9.05 billion, a price-to-earnings ratio of 115.63 and a beta of 1.03. The firm has a fifty day moving average of $174.96 and a two-hundred day moving average of $156.95.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. On average, equities analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on MASI shares. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company boosted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Finally, Piper Sandler boosted their target price on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Hedge Funds Weigh In On Masimo

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jefferies Financial Group Inc. bought a new stake in Masimo during the 4th quarter valued at approximately $1,762,000. Forum Financial Management LP bought a new stake in shares of Masimo during the fourth quarter valued at approximately $217,000. Pacific Point Advisors LLC bought a new stake in shares of Masimo during the fourth quarter valued at approximately $208,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Masimo by 69.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 190,246 shares of the medical equipment provider’s stock worth $31,448,000 after purchasing an additional 77,775 shares during the period. Finally, Woodline Partners LP raised its holdings in Masimo by 450.4% in the fourth quarter. Woodline Partners LP now owns 51,185 shares of the medical equipment provider’s stock worth $8,461,000 after purchasing an additional 41,885 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.